Proteomic analysis of human bile and potential applications for cancer diagnosis

Expert Review of Proteomics

Volumn 6, Issue 3, 2009, Pages 285-301

  Farina, Annarita ^a   Dumonceau, Jean Marc ^b   Lescuyer, Pierre ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Bile; Biomarker; Cholangiocarcinoma; Pancreatic cancer; Proteomics

Indexed keywords

BILE SALT; BILIRUBIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CHOLECYSTOKININ; CHOLESTEROL; INORGANIC SALT; MUCIN 2; PHOSPHOLIPID;

ASPIRATION BIOPSY; BILE; BILE DUCT CARCINOMA; BIOCHEMICAL COMPOSITION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CHOLESTEROL STONE; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXCRETION; GEL PERMEATION CHROMATOGRAPHY; HEPATOBILIARY SYSTEM; HUMAN; IMMUNOCHEMISTRY; LIVER; PANCREAS; PANCREAS ADENOCARCINOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN PURIFICATION; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; ULTRACENTRIFUGATION;

BILE; BIOLOGICAL MARKERS; HUMANS; NEOPLASMS; PROTEOME; PROTEOMICS;

EID: 66949163736     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.09.12     Document Type: Review

References (49)

1. Arrese M, Trauner M. Molecular aspects of bile formation and cholestasis. Trends Mol. Med. 9(12), 558-564 (2003). (Pubitemid 38017195)
2. Hofmann AF. Bile acids: the good, the bad, and the ugly. News Physiol. Sci. 14, 24-29 (1999).
3. Coleman R. Biochemistry of bile secretion. Biochem. J. 244(2), 249-261 (1987). (Pubitemid 17087087)
4. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1(11), 845-867 (2002). •• Essential paper for understanding the crucial aspects of clinical proteomics.
5. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
6. Li D, Xie K, Wolff R et al. Pancreatic cancer. Lancet 363(9414), 1049-1057 (2004). (Pubitemid 38410779)
7. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33(6), 1353-1357 (2001). (Pubitemid 32496970)
8. West J, Wood H, Logan RF et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br. J. Cancer 94(11), 1751-1758 (2006).
9. Shaib YH, Davila JA, McGlynn K et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J. Hepatol. 40(3), 472-477 (2004). (Pubitemid 38230849)
10. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48(1), 308-321 (2008).
11. Stark M, Jörnvall H, Johansson J. Isolation and characterization of hydrophobic polypeptides in human bile. Eur. J. Biochem. 266(1), 209-214 (1999).
12. Zhou H, Chen B, Li RX et al. Large-scale identification of human biliary proteins from a cholesterol stone patient using a proteomic approach. Rapid Commun. Mass Spectrom. 19(23), 3569-3578 (2005). (Pubitemid 41691933)
13. Guerrier L, Claverol S, Finzi L et al. Contribution of solid-phase hexapeptide ligand libraries to the repertoire of human bile proteins. J. Chromatogr. A 1176(1-2), 192-205 (2007). • Large-scale proteomic analysis of bile based on the use of immobilized peptide ligand libraries for the enrichment of low-abundance species.
14. Kristiansen TZ, Bunkenborg J, Gronborg M et al. A proteomic analysis of human bile. Mol. Cell. Proteomics 3(7), 715-728 (2004). •• First large-scale proteomic analysis on bile. Several cancer-associated proteins were identified in bile from a patient with a cholangiocarcinoma.
15. Farina A, Dumonceau JM, Frossard JL et al. Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer. J. Proteome Res. 8(1), 159-169 (2009). •• Large-scale proteomic analysis of bile from patients with pancreatic cancer. Several cancer-associated proteins were identified, two of which were validated by immunoblot.
16. Dumonceau JM. Biliary ERCP. Endoscopy 40(1), 50-54 (2008).
17. Trauner M, Boyer, JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol. Rev. 83, 633-671 (2003). (Pubitemid 36378680)
18. Keulemans YC, Mok KS, De Wit LT et al. Hepatic bile versus gallbladder bile: a comparison of protein and lipid concentration and composition in cholesterol gallstone patients. Hepatology 28, 11-16 (1998). (Pubitemid 28299979)
19. Kristiansen TZ, Maitra A, Pandey A. Proteomics of human bile. In: Proteomics of Human Body Fluids. Visith Thongboonkerd MF (Ed.). Humana Press, NJ, USA, 399-414 (2007).
20. Herbert BR, Righetti PG, Citterio A et al. Sample preparation and prefractionation techniques for electrophoresis-based proteomics. In: Proteome Research: Two-dimensional Gel Electrophoresis and Identification Methods. Rabilloud T (Ed.). Springer, Berlin, Germany, 15-40 (2000).
21. Chen B, Dong JQ, Chen YJ et al. Two-dimensional electrophoresis for comparative proteomic analysis of human bile. Hepatobiliary Pancreat. Dis. Int. 6(4), 402-406 (2007). (Pubitemid 47288125)
22. Shen Y, Kim J, Strittmatter EF et al. Characterization of the human blood plasma proteome. Proteomics 5, 4034-4045 (2005) (Pubitemid 41502498)
23. LaRusso NF. Proteins in bile: how they get there and what they do. Am. J. Physiol. 247, 199-205 (1984). (Pubitemid 14000551)
24. Reuben A. Biliary proteins. Hepatology 4, 46S-50S (1984). (Pubitemid 14018142)
25. Mullock BM, Shaw LJ, Fitzharris B et al. Sources of proteins in human bile. Gut 26, 500-509 (1985). (Pubitemid 15064718)
26. He C, Fischer S, Meyer G et al. Two-dimensional electrophoretic analysis of vesicular and micellar proteins of gallbladder bile. J. Chromatogr. A 776(1), 109-115 (1997). (Pubitemid 27336981)
27. Bonney GK, Craven RA, Prasad R et al. Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol. 9(2), 149-158 (2008). •• Highlights the interest of proteomic analysis of bile for the discovery of new cancer biomarkers.
28. Reidegeld KA, Eisenacher M, Kohl M et al. An easy-to-use Decoy Database Builder software tool, implementing different decoy strategies for false discovery rate calculation in automated MS/MS protein identifications. Proteomics 8, 1129-1137 (2008).
29. Garcea G, Dennison AR, Pattenden CJ et al. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. J. Pancreas 9(2), 99-132 (2008). (Pubitemid 351611725)
30. Patel T, Singh P. Cholangiocarcinoma: emerging approaches to a challenging cancer. Curr. Opin. Gastroenterol. 23(3), 317-323 (2007).
31. Dumonceau JM, Macias Gomez C, Casco C et al. Grasp or brush for biliary sampling at endoscopic retrograde cholangiography? A blinded randomized controlled trial. Am. J. Gastroenterol. 103(2), 333-340 (2008). (Pubitemid 351248706)
32. Eloubeidi MA, Chen VK, Eltoum IA et al. Endoscopic ultrasound-guided fine needle aspiration biopsy of patients with suspected pancreatic cancer: diagnostic accuracy and acute and 30-day complications. Am. J. Gastroenterol. 98(12), 2663-2668 (2003). (Pubitemid 38020105)
33. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur. J. Surg. Oncol. 33(3), 266-270 (2007). (Pubitemid 46488663)
34. Ohshio G, Manabe T, Watanabe Y et al. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice. Am. J. Gastroenterol. 85(10), 1370-1376 (1990). (Pubitemid 20360650)
35. Ker CG, Chen JS, Lee KT et al. Assessment of serum and bile levels of CA19-9 and CA125 in cholangitis and bile duct carcinoma. J. Gastroenterol. Hepatol. 6(5), 505-508 (1991).
36. Brockmann J, Emparan C, Hernandez CA et al. Gallbladder bile tumor marker quantification for detection of pancreatobiliary malignancies. Anticancer Res. 20(6D), 4941-4947 (2000). (Pubitemid 32319055)
37. Chen CY, Shiesh SC, Tsao HC et al. The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma - the influence of sampling time and hepatolithiasis. Hepatogastroenterology 49(45), 616-620 (2002).
38. Higashi M, Yonezawa S, Ho JJ et al. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology 30(6), 1347-1355 (1999).
39. Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am. J. Clin. Pathol. 122(1), 61-69 (2004). (Pubitemid 38849873)
40. Singh AP, Senapati S, Ponnusamy MP et al. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol. 9(11), 1076-1085 (2008).
41. Iacovazzi PA, Trisolini A, Barletta D et al. Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with a-fetoprotein. Clin. Chem. Lab. Med. 39(10), 961-965 (2001). (Pubitemid 33062248)
42. Gentiloni N, Caradonna P, Costamagna G et al. Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. Am. J. Gastroenterol. 90(7), 1069-1072 (1995).
43. Koopmann J, Thuluvath PJ, Zahurak ML et al. MAC-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 101(7), 1609-1615 (2004). • Validation study evaluating one of the proteins identified in [14] as a biomarker for the diagnosis of cholangiocarcinoma.
44. Duxbury MS, Matros E, Clancy T et al. CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions. Ann. Surg. 241(3), 491-496 (2005). (Pubitemid 40299727)
45. Ieta K, Tanaka F, Utsunomiya T et al. CEACAM6 gene expression in intrahepatic cholangiocarcinoma. Br. J. Cancer 95(4), 532-540 (2006). (Pubitemid 44232564)
46. Kuroki M, Matsushita H, Matsumoto H et al. Nonspecific cross-reacting antigen-50/90 (NCA-50/90) as a new tumor marker. Anticancer Res. 19(6C), 5599-5606 (1999). (Pubitemid 30093335)
47. Adachi J, Kumar C, Zhang Y et al. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 7(9), R80 (2006). (Pubitemid 44614864)
48. Chenau J, Michelland S, Sidibe J et al. Peptides OFFGEL electrophoresis: a suitable pre-analytical step for complex eukaryotic samples fractionation compatible with quantitative iTRAQ labeling. Proteome Sci. 26, 6-9 (2008).
49. Dayon L, Hainard A, Licker V et al. Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags. Anal. Chem. 80(8), 2921-2931 (2008). (Pubitemid 351556457)